CoChat

Serum lysyl oxidase-like 2 levels and idiopathic pulmonary fibrosis disease progression

Chien, Jason W., Richards, Thomas J., Gibson, Kevin F., Zhang, Yingze, Lindell, Kathleen O., Shao, Lixin, Lyman, Susan K., Adamkewicz, Joanne I., Smith, Victoria, Kaminski, Naftali, O’Riordan, Thomas · 2014 · European Respiratory Journal
Cited by 156

The DOI matches its Crossref record; 8 of the 8 references it cites were found in a registry or an index.

Abstract

We evaluated whether lysyl oxidase-like 2 (LOXL2), which promotes cross-linking of collagen in pathological stroma, was detectable in serum from idiopathic pulmonary fibrosis (IPF) patients, and assessed its relationship with IPF disease progression. Patients from the ARTEMIS-IPF (n=69) and the Genomic and Proteomic Analysis of Disease Progression in IPF (GAP) (n=104) studies were analysed. Baseline serum LOXL2 (sLOXL2) levels were compared with baseline clinical and physiological surrogates of disease severity, and the association with IPF disease progression was assessed using a classification and regression tree (CART) method. sLOXL2 correlated weakly with forced vital capacity and carbon monoxide diffusion capacity (r -0.24–0.05) in both cohorts. CART-determined thresholds were similar: ARTEMIS-IPF 800 pg·mL −1 and GAP 700 pg·mL −1 . In ARTEMIS-IPF, higher sLOXL2 (>800 pg·mL −1 ) was associated with increased risk for disease progression (hazard ratio (HR) 5.41, 95% CI 1.65–17.73). Among GAP subjects with baseline spirometric data (n=70), higher sLOXL2 levels (>700 pg·mL −1 ) were associated with more disease progression events (HR 1.78, 95% CI 1.01–3.11). Among all GAP subjects, higher sLOXL2 levels were associated with increased risk for mortality (HR 2.28, 95% CI 1.18–4.38). These results suggest that higher sLOXL2 levels are associated with increased risk for IPF disease progression. However, due to multiple limitations, these results require validation.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1183/09031936.00141013

Cites

8 of 8 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 8 references

Cited by

See all 156

Metadata

Authors
Chien, J. W., Richards, T. J., Gibson, K. F., Zhang, Y., Lindell, K. O., Shao, L., Lyman, S. K., Adamkewicz, J. I., Smith, V., Kaminski, N., & O’Riordan, T.
Venue
European Respiratory Journal
Published
2013-10-31
Volume
43
Issue
5
Pages
1430-1438
ISSN
  • 0903-1936 (ISSN-L)
  • 1399-3003
OpenAlex
W2168911526
Cited by
156
References
8
FWCI
8.28
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Serum lysyl oxidase-like 2 levels and idiopathic pulmonary fibrosis disease progression. https://app.cochat.ai/papers/10.1183/09031936.00141013
The paper
Chien, J. W., Richards, T. J., Gibson, K. F., Zhang, Y., Lindell, K. O., Shao, L., Lyman, S. K., Adamkewicz, J. I., Smith, V., Kaminski, N., & O’Riordan, T. (2014). Serum lysyl oxidase-like 2 levels and idiopathic pulmonary fibrosis disease progression. European Respiratory Journal. https://doi.org/10.1183/09031936.00141013

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.